Showing results (111-120 of 146) with videos related to

Sort By:
Pageof 15
Frontiers in Immunology|July 26, 2021
Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary ImmunodeficienciesElena E Perez, Jacques Hébert, Anne K Ellis, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 13, 2026
Pharmacokinetics and pharmacodynamics following repeat dosing of neffy (epinephrine nasal spray) versus intramuscular injection during induced allergic rhinitisJohn Oppenheimer, Thomas B Casale, Jonathan M Spergel, et al.
Psychiatry Research|August 11, 2023
The mental health impact of the COVID-19 pandemic on post-secondary students: A longitudinal studyAntonio Lorenzo, Altea Kthupi, Weihan Liu, et al.
ERJ Open Research|August 5, 2025
Real-world comparative effectiveness of biologic therapies in severe asthma: EU-ADVANTAGEGiorgio Walter Canonica, Johann Christian Virchow, Arnaud Bourdin, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 6, 2026
Anaphylaxis and Epinephrine Use in PregnancyLuciana Kase Tanno, Anne K Ellis, Lubnaa Hossenbaccus, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|July 16, 2014
Add-on histamine receptor-3 antagonist for allergic rhinitis: a double blind randomized crossover trial using the environmental exposure unitMichelle L North, Terry J Walker, Lisa M Steacy, et al.
Pharmaceutics|June 27, 2024
Development of <i>neffy</i>, an Epinephrine Nasal Spray, for Severe Allergic ReactionsAnne K Ellis, Thomas B Casale, Michael Kaliner, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|March 13, 2017
The Kingston Allergy Birth Cohort: Exploring parentally reported respiratory outcomes through the lens of the exposomeMichelle L North, Jeffrey R Brook, Elizabeth Y Lee, et al.
Allergy and Asthma Proceedings|November 8, 2005
Comparative efficacy of cetirizine and fexofenadine for seasonal allergic rhinitis, 5-12 hours postdose, in the environmental exposure unitJames H Day, Maureen P Briscoe, Elizabeth Rafeiro, et al.
Frontiers in Allergy|April 7, 2022
Review: The Nose as a Route for Therapy. Part 2 ImmunotherapyYorissa Padayachee, Sabine Flicker, Sophia Linton, et al.
Pageof 15